



FarmaForce Limited
Level 3, 222 Clarence Street
Sydney, NSW, 2000

30 August 2017

ASX ANNOUNCEMENT - FARMAFORCE APPOINTS NEW AUDITOR

FarmaForce Limited (ASX: **FFC**), announces that its existing auditor Mr Timothy Davidson, Fortunity Assurance (**Fortunity Assurance**) is unable to continue to act as auditor of the parent company iQNovate Limited (IQN) due to the auditor rotation obligations under time out provisions pursuant to section 324DA(1) of the Corporations Act. Accordingly, FFC has received a letter of resignation from Fortunity Assurance.

FFC and Fortunity Assurance believe it is in the best interests of the company to retain the same auditor as IQN.


RSM Australia Partners has consented to act as the auditor of FFC in respect of the 2017 financial year and going forward.

ASIC has consented to the resignation of Fortunity Assurance as auditor of FFC. The resignation of Fortunity Assurance and the appointment of RSM Australia Partners as FFC's auditor will take effect from the date of this announcement.

FFC expects to release its preliminary full year financial report to 30 June 2017 to the market on 31 August 2017.

FFC wishes to thank Fortunity Assurance for its services to date and welcomes RSM Australia Partners as its auditor.

Yours Faithfully



Harry Simeonidis

Director

About FarmaForce

FarmaForce is a contract sales organisation (CSO) offering innovative sales solutions to the Australian Pharmaceutical Industry. FarmaForce provides clients with a broad and unique range of sales force solutions extending from shared or syndicated teams right through to fully managed dedicated teams on a national level. FarmaForce promote clients' products to their healthcare professional customers, being general practitioners, specialists and pharmacists. FarmaForce also provide nurse teams, pharmacy merchandising teams and digital detailing solutions.

www.farmaforce.com.au

About The iQ Group Global

The iQ Group Global supports, promotes and grows the Australian biotechnology sector. They are the trusted partner to their investors, biotechnology and global pharmaceutical clients – adding value through their ability to find, invest, partner, grow and divest early stage biotechnology assets. At every step in the journey, the expertise of The iQ Group Global delivers advice, experience and support designed to add value to the core biotechnology investment.

www.theiqgroupglobal.com.au

FarmaForce Limited

ABN: 95 167 748 843 | Level 3, 222 Clarence Street, Sydney, NSW, 2000 |
Phone: 02 8239 5400 | Fax: 02 8362 9547 | Email: info@farmaforce.com.au | Web:
www.farmaforce.com.au

